mebendazole

Drugs originally developed to treat parasitic infections, including ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and other antiparasitic agents, have demonstrated compelling anticancer properties across a wide range of preclinical models...Despite substantial in-vitro and in-vivo evidence, the clinical translation of these agents faces significant challenges, including pharmacokinetic limitations, heterogeneous dosing regimens, and the paucity of adequately powered randomized clinical trials. This review systematically examines the current mechanistic understanding, experimental evidence, and clinical data supporting the repositioning of antiparasitic drugs as anticancer agents, while critically evaluating the limitations of existing evidence and outlining future research priorities.

She underwent a combinatorial protocol at ChemoThermia Oncology Center (Istanbul, Turkey) comprising of Metabolically Supported Chemotherapy (MSCT) consisting of docetaxel, doxorubicin, and cyclophosphamide administered following a 14-hour fast and low dose insulin-induced mild hypoglycemia, alongside a strict ketogenic diet (GKI < 2.0). Adjunctive therapies included local and whole-body hyperthermia, hyperbaric oxygen therapy (HBOT), and a combination of repurposed drugs (metformin, aspirin, doxycycline, mebendazole, ivermectin, and famotidine) designed to target metabolic, inflammatory, and survival pathways...A durable response in a patient with otherwise poor prognosis was achieved after systematically targeting cancer cell bioenergetics and the tumor microenvironment. These findings support further clinical investigation into multimodal metabolic therapies for advanced HR+ breast cancer.

Integrative analysis of LR crosstalk, knockdown experiments, and molecular docking reveals potential drug targets.

P3, N=315, Swiss Tropical and Public Health Institute

Combination treatment with mebendazole and oxaliplatin significantly enhanced chemosensitivity in ESCC cells. Collectively, these findings establish the USP5-IMPDH2-guanine axis as a critical driver of ESCC progression and highlight its potential as a promising therapeutic target for ESCC.

This multi-cancer investigation identifies ENOX2-MMP2 signaling as a functional driver of invasion and metastasis and demonstrates that mebendazole reprograms oncogenic-tumor suppressor networks. By integrating biomarker profiling with drug repurposing, our study highlights the translational potential of mebendazole as a cost-effective anticancer agent and supports the development of multi-gene biomarkers for diagnosis and therapy in aggressive malignancies.

MBZ holds significant potential for reshaping immunotherapy by exerting a profound impact on dendritic cells. By comprehending the intricate interaction between MBZ and dendritic cell function, innovative interventions can be developed.

Our findings suggest that MBZ modulates nucleotide synthesis pathways, contributing to its selective antiproliferative effects in GC cells. This study highlights potential new pharmacological targets for drug repurposing and further investigation into the broader therapeutic applications of MBZ.

P3, N=2500, Completed, Cornell University | Active, not recruiting --> Completed

P=N/A, N=46, Recruiting, Tanta University | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: Apr 2025 --> Apr 2026

Mebendazole inhibited the viability of HCC827 and A549 cells with diminished expression of PELI3 and increased expression of TRADD. PELI3 can function as an E3 ubiquitin ligase to ubiquitinate TRADD, and Mebendazole might be a promising drug to affect PELI3 expression in NSCLC.

The combination of mebendazole and gefitinib effectively suppresses tumor cell viability and modulates key pathways involved in cancer progression. By targeting cytoskeletal integrity and EGFR signaling, it may disrupt cytokine and tumor-microenvironment interactions, supporting further exploration as a strategy to overcome resistance in lung and breast cancers.